Omalizumab for cholinergic urticaria: 6 months prospective study and systematic review of the literature
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Omalizumab for cholinergic urticaria : 6 months prospective study and systematic review of the literature. / Ghazanfar, Misbah Noshela; Holm, Jesper Gronlund; Thomsen, Simon Francis.
I: Dermatologic Therapy, Bind 33, Nr. 6, 14010, 2020.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Omalizumab for cholinergic urticaria
T2 - 6 months prospective study and systematic review of the literature
AU - Ghazanfar, Misbah Noshela
AU - Holm, Jesper Gronlund
AU - Thomsen, Simon Francis
PY - 2020
Y1 - 2020
N2 - To examine the effectiveness of omalizumab on disease activity and quality of life in patients with cholinergic urticaria (CholU). Further, a systematic review of the literature was performed to identify all studies of use of omalizumab in CholU. A total of 23 patients (63.9%) were refractory to updosed non-sedating antihistamines and initiated omalizumab in the observation period. Among these, an improvement of 10.8 UAS7 points (4.6-17.0),P= .002, was seen at 6 months follow up. DLQI and disease bother score VAS also improved significantly from before initiating treatment with omalizumab to follow-up; 7.0 points (3.6-10.3),P <.001 and 3.1 points (1.5-4.8),P= .001, respectively. The overall mean drug survival time for omalizumab (discontinued due to any cause) was 30.6 months (22.2-39.0). A total of five patients (21.7%) reported suspected side effects (headache, muscle pain, fatigue and injection site reactions) during treatment with omalizumab until 6 months follow-up. The systematic literature review identified 58 additional antihistamine refractory patients with CholU treated with omalizumab. The available studies reported that omalizumab is effective in patients with CholU and improves their disease-related quality of life. Omalizumab is safe, reduces disease activity and improves disease-related quality of life in patients with CholU.
AB - To examine the effectiveness of omalizumab on disease activity and quality of life in patients with cholinergic urticaria (CholU). Further, a systematic review of the literature was performed to identify all studies of use of omalizumab in CholU. A total of 23 patients (63.9%) were refractory to updosed non-sedating antihistamines and initiated omalizumab in the observation period. Among these, an improvement of 10.8 UAS7 points (4.6-17.0),P= .002, was seen at 6 months follow up. DLQI and disease bother score VAS also improved significantly from before initiating treatment with omalizumab to follow-up; 7.0 points (3.6-10.3),P <.001 and 3.1 points (1.5-4.8),P= .001, respectively. The overall mean drug survival time for omalizumab (discontinued due to any cause) was 30.6 months (22.2-39.0). A total of five patients (21.7%) reported suspected side effects (headache, muscle pain, fatigue and injection site reactions) during treatment with omalizumab until 6 months follow-up. The systematic literature review identified 58 additional antihistamine refractory patients with CholU treated with omalizumab. The available studies reported that omalizumab is effective in patients with CholU and improves their disease-related quality of life. Omalizumab is safe, reduces disease activity and improves disease-related quality of life in patients with CholU.
KW - anti-IgE
KW - cholinergic urticaria
KW - omalizumab
KW - systematic review
KW - DISEASE-ACTIVITY
KW - PATIENT
U2 - 10.1111/dth.14010
DO - 10.1111/dth.14010
M3 - Review
C2 - 32654349
VL - 33
JO - Dermatologic Therapy
JF - Dermatologic Therapy
SN - 1396-0296
IS - 6
M1 - 14010
ER -
ID: 247438178